Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Industry, Sector and Symbol
Industry Computer programming, data processing, & other computer related
Sub-IndustryN/A
SectorBusiness Services
Phone888-798-5802
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130.37 million
Profitability
Miscellaneous
Employees342
OptionableNot Optionable
Cardlytics (NASDAQ:CDLX) Frequently Asked Questions
What is Cardlytics' stock symbol?
Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."
How were Cardlytics' earnings last quarter?
Cardlytics Inc (NASDAQ:CDLX) released its earnings results on Tuesday, November, 13th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.48. The firm earned $34.58 million during the quarter, compared to the consensus estimate of $37.62 million. Cardlytics's revenue was up 10.1% compared to the same quarter last year. View Cardlytics' Earnings History.
When is Cardlytics' next earnings date?
What guidance has Cardlytics issued on next quarter's earnings?
Cardlytics updated its FY 2018 earnings guidance on Tuesday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $146-148 million, compared to the consensus revenue estimate of $154.43 million.Cardlytics also updated its Q4 2018 guidance to EPS.
What price target have analysts set for CDLX?
8 Wall Street analysts have issued 12 month price objectives for Cardlytics' shares. Their predictions range from $15.00 to $28.00. On average, they expect Cardlytics' stock price to reach $23.2857 in the next twelve months. This suggests a possible upside of 33.5% from the stock's current price. View Analyst Price Targets for Cardlytics.
What is the consensus analysts' recommendation for Cardlytics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cardlytics.
What are Wall Street analysts saying about Cardlytics stock?
Here are some recent quotes from research analysts about Cardlytics stock:
- 1. According to Zacks Investment Research, "Cardlytics, Inc. is engaged in developing a purchase intelligence platform. The purchase data includes debit, credit and bill pay data from online and in-store transactions. It helps the marketers identify, reach and influence likely buyers at scale, and measure the impact of marketing spends. The Company also operates an advertising channel, Cardlytics Direct. Cardlytics Direct delivers tailored marketing for marketers and financial institutions. Cardlytics, Inc. is based in ATLANTA, United States. " (1/15/2019)
- 2. SunTrust Banks, Inc. analysts commented, "We hosted CDLX mgt for an NDR this week, during which mgt provided more color around the state of the business following 2Q earnings on 8/14, and progress on the all-important JPM Fargo relationships. As a digital ad channel designed to be bot and fraud proof with attractive ROI, CDLX is gaining enough scale with users and becoming a more relevant platform for advertisers, in our view. The focus now is on-boarding these two new partners while aggressively expanding the sales force to sell the growing ad inventory. We remain positive on CDLX and see ample opportunity for growth. Becoming The Industry Consolidator." (9/11/2018)
Has Cardlytics been receiving favorable news coverage?
News stories about CDLX stock have trended very positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cardlytics earned a coverage optimism score of 3.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Cardlytics' key competitors?
Some companies that are related to Cardlytics include Internet Initiative Japan (IIJI), 21Vianet Group (VNET), TrueCar (TRUE), Jianpu Technology (JT), HealthStream (HSTM), Aurora Mobile (JG), Model N (MODN), Pintec Technology (PT), The Rubicon Project (RUBI), Internap (INAP), Synacor (SYNC), Sify Technologies (SIFY), Autoweb (AUTO), GigaMedia (GIGM) and Chinanet Online (CNET).
Who are Cardlytics' key executives?
Cardlytics' management team includes the folowing people:
- Mr. Scott D. Grimes, Co-Founder, CEO & Director (Age 55)
- Ms. Lynne Marie Laube, Co-Founder, COO & Director (Age 48)
- Mr. David Evans, CFO & Head of Corp. Devel.
- Mr. Sathish Gaddipati, Chief Technology Officer (Age 51)
- Mr. Kirk L. Somers, Chief Legal & Privacy Officer (Age 53)
When did Cardlytics IPO?
(CDLX) raised $76 million in an initial public offering on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.
Who are Cardlytics' major shareholders?
Cardlytics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Canaan Partners VIII LLC (11.69%) and Regents of The University of California (0.18%). Company insiders that own Cardlytics stock include David Thomas Evans, Kirk Somers, Lynne Marie Laube, Polaris Venture Management Co and Scott D Grimes. View Institutional Ownership Trends for Cardlytics.
Which institutional investors are selling Cardlytics stock?
CDLX stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California. Company insiders that have sold Cardlytics company stock in the last year include David Thomas Evans, Kirk Somers, Lynne Marie Laube, Polaris Venture Management Co and Scott D Grimes. View Insider Buying and Selling for Cardlytics.
Which institutional investors are buying Cardlytics stock?
CDLX stock was purchased by a variety of institutional investors in the last quarter, including Canaan Partners VIII LLC. Company insiders that have bought Cardlytics stock in the last two years include David Thomas Evans and Scott D Grimes. View Insider Buying and Selling for Cardlytics.
How do I buy shares of Cardlytics?
Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardlytics' stock price today?
One share of CDLX stock can currently be purchased for approximately $17.44.
How big of a company is Cardlytics?
Cardlytics has a market capitalization of $331.72 million and generates $130.37 million in revenue each year. The company earns $-19,640,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis. Cardlytics employs 342 workers across the globe.
What is Cardlytics' official website?
How can I contact Cardlytics?
Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]
MarketBeat Community Rating for Cardlytics (NASDAQ CDLX)
MarketBeat's community ratings are surveys of what our community members think about Cardlytics and other stocks. Vote "Outperform" if you believe CDLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
